Provided by Tiger Trade Technology Pte. Ltd.

Lexeo Therapeutics

5.54
-0.1100-1.95%
Post-market: 5.540.00000.00%16:52 EDT
Volume:737.19K
Turnover:4.08M
Market Cap:404.35M
PE:-2.22
High:5.82
Open:5.72
Low:5.43
Close:5.65
52wk High:10.99
52wk Low:1.45
Shares:72.99M
Float Shares:45.01M
Volume Ratio:0.81
T/O Rate:1.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5000
EPS(LYR):-3.0934
ROE:-80.69%
ROA:-44.66%
PB:3.35
PE(LYR):-1.79

Loading ...

Lexeo Therapeutics selloff looks ‘highly unwarranted,’ says H.C. Wainwright

TIPRANKS
·
Nov 04, 2025

Lexeo Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 21, 2025

Press Release: Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering

Dow Jones
·
Oct 21, 2025

Lexeo Therapeutics Executives Make Major Stock Moves!

TIPRANKS
·
Oct 18, 2025

Lexeo Therapeutics Chief Development Officer Sandi See Tai Reports Sale of Common Shares

Reuters
·
Oct 18, 2025

Lexeo Therapeutics CEO Richard Nolan Reports Disposal of Common Shares

Reuters
·
Oct 18, 2025

Lexeo Therapeutics price target lowered to $18 from $20 at Leerink

TIPRANKS
·
Oct 18, 2025

Lexeo Therapeutics Shares up 2.5% After Co's Stock Sale, Private Placement

THOMSON REUTERS
·
Oct 17, 2025

Lexeo Therapeutics 15.625M share Spot Secondary priced at $8.00

TIPRANKS
·
Oct 17, 2025

Lexeo Therapeutics Shares Fall 5.9% Premarket After Co's Stock Sale, Private Placement

THOMSON REUTERS
·
Oct 17, 2025

Lexeo Therapeutics Inc Announces Public Offering And Private Placement For $135 Million

Reuters
·
Oct 17, 2025

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

THOMSON REUTERS
·
Oct 17, 2025

Lexeo Therapeutics Inc - Offers 15,625,000 Shares at $8.00 per Share

THOMSON REUTERS
·
Oct 17, 2025

Lexeo Therapeutics Announces Public Offering and Concurrent Private Placement of Common Stock and Pre-Funded Warrants

Reuters
·
Oct 17, 2025

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Oct 17, 2025

Lexeo Therapeutics Initiated at Buy by Guggenheim

Dow Jones
·
Oct 15, 2025

Guggenheim Initiates Coverage on Lexeo Therapeutics With Buy Rating, $30 Price Target

MT Newswires Live
·
Oct 15, 2025

Chardan Raises Price Target on Lexeo Therapeutics to $17 From $15, Keeps Buy Rating

MT Newswires Live
·
Oct 08, 2025

Buy Rating for Lexeo Therapeutics Driven by Regulatory Progress and Promising Clinical Data on LX2006

TIPRANKS
·
Oct 08, 2025

Lexeo Therapeutics Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Oct 07, 2025